
Denali Therapeutics Inc.: updates and filings
Price
$18.45
November 20, 2026Market cap $2.9B
What Ploutos Investor adds for Denali Therapeutics
Part of Ploutos Investor, €9.99 a month
- The full history: 10 fiscal years, from 2016
- The estimated fair value, with its range and its certainty
- The full analysis, 18 a month
- More questions to the chat on its filings
- Excel with every year
- An email when it reports, changes its dividend or an officer buys
Sign in with a free account to see the last 5 fiscal years.
What comes next, and what happened
Its next results and latest dividend, and the filings that told of something: results, deals, people, debt. In plain words, each linked to the filing.
Next results
last Nov 3, 2026next Feb 4, 2027
A rough estimate from when it has reported before, which has varied. The company announces the date itself.
November 2026
August 2026
June 2026
May 2026
April 2026
Its SEC filings
What it has filed lately, newest first, linked to the document itself.
- Nov 16, 2026Over-5% holder statement (passive) (amendment)FormSCHEDULE 13G/A
- Nov 3, 2026Quarterly reportfor the period to Sep 30, 2026Form10-Q
- Nov 3, 2026Results of operationsForm8-K
- Aug 6, 2026Quarterly reportfor the period to Jun 30, 2026Form10-Q
- Aug 6, 2026Results of operationsForm8-K
- Aug 4, 2026Over-5% holder statement (passive) (amendment)FormSCHEDULE 13G/A
- Jul 28, 2026Acquisition or disposal of assetsForm8-K
- Jul 8, 2026Over-5% holder statement (passive) (amendment)FormSCHEDULE 13G/A
- Jun 18, 2026Material agreement entered, Regulation FD disclosureForm8-K
- Jun 4, 2026Shareholder voteForm8-K
- May 22, 2026Regulation FD disclosureForm8-K
- May 15, 2026Over-5% holder statement (passive)FormSCHEDULE 13G
- May 7, 2026Quarterly reportfor the period to Mar 31, 2026Form10-Q
- May 7, 2026Results of operationsForm8-K
- May 6, 2026Over-5% holder statement (passive) (amendment)FormSCHEDULE 13G/A
- Apr 21, 2026Additional annual meeting materialFormDEFA14A
- Apr 21, 2026Annual report to shareholdersfor the period to Dec 31, 2025FormARS
- Apr 21, 2026Annual meeting proxy statementFormDEF 14A
- Apr 3, 2026Material agreement endedForm8-K
- Mar 31, 2026New material financial obligation, Regulation FD disclosureForm8-K
- Mar 26, 2026Over-5% holder statement (passive) (amendment)FormSCHEDULE 13G/A
- Mar 25, 2026Regulation FD disclosureForm8-K
- Feb 26, 2026Annual reportfor the period to Dec 31, 2025Form10-K
- Feb 26, 2026Shares registered for employeesFormS-8
- Feb 26, 2026Results of operationsForm8-K
| Filed | Form | What it is | Filing |
|---|---|---|---|
| Nov 16, 2026 | SCHEDULE 13G/A | Over-5% holder statement (passive) (amendment) | Document |
| Nov 3, 2026 | 10-Q | Quarterly reportfor the period to Sep 30, 2026 | Document |
| Nov 3, 2026 | 8-K | Results of operations | Document |
| Aug 6, 2026 | 10-Q | Quarterly reportfor the period to Jun 30, 2026 | Document |
| Aug 6, 2026 | 8-K | Results of operations | Document |
| Aug 4, 2026 | SCHEDULE 13G/A | Over-5% holder statement (passive) (amendment) | Document |
| Jul 28, 2026 | 8-K | Acquisition or disposal of assets | Document |
| Jul 8, 2026 | SCHEDULE 13G/A | Over-5% holder statement (passive) (amendment) | Document |
| Jun 18, 2026 | 8-K | Material agreement entered, Regulation FD disclosure | Document |
| Jun 4, 2026 | 8-K | Shareholder vote | Document |
| May 22, 2026 | 8-K | Regulation FD disclosure | Document |
| May 15, 2026 | SCHEDULE 13G | Over-5% holder statement (passive) | Document |
| May 7, 2026 | 10-Q | Quarterly reportfor the period to Mar 31, 2026 | Document |
| May 7, 2026 | 8-K | Results of operations | Document |
| May 6, 2026 | SCHEDULE 13G/A | Over-5% holder statement (passive) (amendment) | Document |
| Apr 21, 2026 | DEFA14A | Additional annual meeting material | Document |
| Apr 21, 2026 | ARS | Annual report to shareholdersfor the period to Dec 31, 2025 | Document |
| Apr 21, 2026 | DEF 14A | Annual meeting proxy statement | Document |
| Apr 3, 2026 | 8-K | Material agreement ended | Document |
| Mar 31, 2026 | 8-K | New material financial obligation, Regulation FD disclosure | Document |
| Mar 26, 2026 | SCHEDULE 13G/A | Over-5% holder statement (passive) (amendment) | Document |
| Mar 25, 2026 | 8-K | Regulation FD disclosure | Document |
| Feb 26, 2026 | 10-K | Annual reportfor the period to Dec 31, 2025 | Document |
| Feb 26, 2026 | S-8 | Shares registered for employees | Document |
| Feb 26, 2026 | 8-K | Results of operations | Document |
From the company's record at the SEC (EDGAR). The topics of each 8-K are the item codes the company itself filed. Its whole record at the SEC, since Sep 8, 2017.
The full analysis
What do Denali Therapeutics's filings show?
The filings are where every one of Denali Therapeutics's figures comes from. The full Ploutos AI analysis reads everything the company has filed and shows what stands behind it, with a source for every figure.
- A fair value range built from the filings
- Earnings quality, debt and red flags
- Insider and institutional moves
- The case for and the case against
Related pages
The other pages on US stocks, free to read. On the company pages, the last three fiscal years are open to everyone, five with a free account, and every year with Ploutos Investor.
The figures come from the company's SEC filings and the share price, and describe what it has reported. They are not a score or a fair value.